NKTX
Nkarta, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.92
+4.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.3M | 9.2M | — | 5.9M | — |
| Gross Profit | (2.3M) | (9.2M) | — | (5.9M) | — |
| Operating Expenses | |||||
| R&D Expense | 97.2M | 90.4M | 96.7M | 90.9M | 90.9M |
| SG&A Expense | 32.7M | 31.6M | 31.4M | 34.9M | 28.1M |
| General & Admin Expense | 32.7M | 31.6M | 31.4M | 34.9M | 28.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (10.0M) | — | — | — |
| Total Operating Expenses | 129.9M | 112.0M | 128.2M | 125.8M | 119.0M |
| Cost and Expenses | 132.3M | 121.2M | 128.2M | 131.7M | 119.0M |
| Operating Income (EBIT) | (132.3M) | (121.2M) | (128.2M) | (131.7M) | (119.0M) |
| Non-Operating | |||||
| Interest Income | 12.5M | 15.5M | 19.3M | 14.1M | 5.6M |
| Interest Expense | — | — | — | — | 5.6M |
| Net Interest Income | 12.5M | 15.5M | 19.3M | 14.1M | — |
| Other Non-Op Income/Expense | 14.9M | 17.1M | 19.4M | 14.1M | 5.1M |
| Non-Operating Income (excl Interest) | (14.9M) | (17.1M) | (19.4M) | (5.3M) | (10.7M) |
| EBT (Pre-Tax Income) | (117.3M) | (104.1M) | (108.8M) | (117.5M) | (113.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (117.3M) | (104.1M) | (108.8M) | (117.5M) | (113.8M) |
| Earnings from Cont. Ops | (117.3M) | (104.1M) | (108.8M) | (117.5M) | (113.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (117.3M) | (104.1M) | (108.8M) | (117.5M) | (113.8M) |
| Per Share | |||||
| Basic EPS | ($1.57) | ($1.41) | ($1.60) | ($2.40) | ($2.61) |
| Diluted EPS | ($1.57) | ($1.41) | ($1.60) | ($2.40) | ($2.61) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 74.5M | 74.0M | 67.9M | 49.0M | 43.6M |
| Diluted Shares Outstanding | 74.5M | 74.0M | 67.9M | 49.0M | 43.6M |
| Profitability Metrics | |||||
| EBITDA | (107.7M) | (94.9M) | (99.6M) | (120.5M) | (105.6M) |
| D&A | 9.6M | 9.2M | 9.2M | 5.9M | 2.6M |
| EBIT | (117.3M) | (104.1M) | (108.8M) | (126.3M) | (108.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026